Class 1 | Class 2 | Class 3 | P | |
---|---|---|---|---|
Dryness dominant | High symptom burden | Low symptom burden | ||
(n = 66) | (n = 134) | (n = 121) | ||
Pain | 0 [0–3] | 5 [4–7] | 2 [0–3] | < 0.001 |
Fatigue | 5 [4–6] | 7 [6–8] | 5 [3–5.5] | < 0.001 |
Dryness | 8 [8–10] | 8 [7–9] | 5 [5–7] | < 0.001 |
Anxiety/depression | 2 [1, 2] | 3 [2, 3] | 2 [1, 2] | < 0.001 |
Age | 55 [47.75–60] | 51 [42.75–60] | 54 [43–59.5] | 0.224 |
Female (%) | 65 (98.5%) | 133 (99.3%) | 119 (98.3%) | 0.789 |
Disease duration (mo) | 23.5 [2.3–56.2] | 22.7 [1.6–61.1] | 10.4 [1.3–44.5] | 0.162 |
uSFR (mL/5 min) | n = 46 0.1 [0–0.25] | n = 97 0.1 [0–0.4] | n = 89 0.25 [0.1–0.5] | < 0.001 |
sSFR (mL/5 min) | n = 40 1.5 [0.85–4.38] | n = 83 2.8 [1.5–5] | n = 70 2.75 [1.15–6.05] | 0.091 |
Xerostomia Inventory | 40.5 [31.75–44] | 40.5 [34–46] | 32 [25–39] | < 0.001 |
Anti Ro positivity | 56/66 (84.8%) | 113/134 (84.3%) | 105/121 (86.8%) | 0.851 |
IgG | 1634 [1310–2038.5] | 1612 [1378–2052] | 1520 [1329–1816.5] | 0.155 |
ACPA positivity | 5/66 (7.6%) | 11/124 (8.9%) | 12/117 (10.3%) | 0.826 |
RF positivity | 43/64 (67.2%) | 79/129 (61.2%) | 79/120 (65.8%) | 0.644 |
Cryoglobulin positivity | n = 63 2 (3.2%) | n = 130 1 (0.8%) | n = 113 0 (0%) | 0.116 |
Complement 3 | 87 [78–99.5] | 94 [80–101] | 93 [82–102] | 0.163 |
Complement 4 | 22.7 [18.8–29.8] | 21.3 [17.4–25.6] | 22.3 [18.4–26.3] | 0.398 |
Schirmer's test (OD) | n = 62 3 [1.75–5] | n = 112 4.5 [2–8] | n = 104 3.5 [2.25–7] | 0.006 |
OSS (OD) | 4 [2–6.25] | 3 [1–5] | 3 [1–5] | 0.004 |
OSDI | 35 [21.5–56.5] | 48 [32–64] | 28 [14–43] | < 0.001 |
EGM | ||||
Arthralgia/arthritis | 13(19.7%) | 81 (60.4%) | 50 (41.3%) | < 0.001 |
Raynaud | 13 (21.3%) | 29(21.6%) | 19 (15.7%) | 0.495 |
Lymphadenopathy | 8 (12.1%) | 24 (17.9%) | 17 (14.0%) | 0.512 |
Pulmonary involvement | 2 (3.0%) | 5 (3.7%) | 6 (5%) | 0.783 |
Cutaneous involvement | 6 (9.1%) | 28 (20.9%) | 13 (10.7%) | 0.027 |
Liver involvement | 4 (6.1%) | 8 (6%) | 3 (2.5%) | 0.358 |
Kidney involvement | 0 | 6(4.5%) | 1 (0.8%) | 0.055 |
Peripheral neuropathy | 3 (4.5%) | 25 (18.7%) | 7 (5.8%) | 0.001 |
CNS | 0 | 3(2.2%) | 1 (0.8%) | 0.356 |
Autoimmune thyroid disease | 15(22.7%) | 17(12.7%) | 18(15%) | 0.179 |
Fibromyalgia | 1 (1.5%) | 12 (9.0%) | 3 (2.5%) | 0.021 |
ESSPRI | 5 [4.3–5.7] | 6.7 [6–7.7] | 4 [3–4.7] | < 0.001 |
ESSDAI | 3 [1–6] | 4 [2–8] | 3 [1–5.75] | 0.03 |
Articular | 0 | 0[0–1] | 0 | 0.004 |
PNS | 0 | 0 | 0 | 0.027 |
Biological | 1 [0–2] | 1 [0–2] | 0 [0–1] | 0.041 |
Pt GA | 72 [56.75–85.25] | 73 [62–83.25] | 52 [33–63.5] | < 0.001 |
Phy GA | 30 [15–45] | 39 [20–50] | 30 [ 13.25–44.75] | 0.014 |
SSDDI | 3 [2, 3] | 2 [2, 3] | 2 [2, 3] | 0.014 |
Hydroxychloroquine | 41/66 (62.1%) | 85/134 (63.4%) | 77/121 (63.6%) | 0.977 |
Methotrexate | 0/66 | 6/134 | 2/121 | 0.137 |
Azathioprine | 2/66 | 4/134 | 1/121 | 0.434 |
Corticosteroid | 24/66 (36.4%) | 63/134 (47.0%) | 33/121 (27.3%) | 0.0049 |
NSAID | 3 (4.5%) | 25 (18.7%) | 16 (13.2%) | 0.024 |
Pilocarpine | 54/66 (81.8%) | 115/134 (85.8%) | 90/121 (74.4%) | 0.067 |
Pilocarpine,dose (mg) | 10 [5–10] | 7.5 [5–10] | 6.25 [2–7.5] | 0.013 |
Salivary siglec-5 (pg/mL) | (n = 35) 4210 [1232.5–9085.9] | (n = 69) 978.3 [213.5–3181.4] | (n = 63) 925.1 [29.7–3450.6] | 0.001 |